Rivus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Rivus Pharmaceuticals's estimated annual revenue is currently $1.2M per year.
- Rivus Pharmaceuticals's estimated revenue per employee is $77,500
- Rivus Pharmaceuticals's total funding is $35M.
Employee Data
- Rivus Pharmaceuticals has 15 Employees.
- Rivus Pharmaceuticals grew their employee count by 15% last year.
Rivus Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | VP, Pharmaceutical Development | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Senior Director & Controller | Reveal Email/Phone |
6 | Director, IP | Reveal Email/Phone |
7 | Chief Operating Officer, Rivus Pharmaceuticals, Inc. | Reveal Email/Phone |
8 | Chief Medical Officer | Reveal Email/Phone |
9 | Senior Research Associate | Reveal Email/Phone |
10 | Executive Business Partner | Reveal Email/Phone |
Rivus Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Rivus Pharmaceuticals?
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus’ CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF). For more information please visit https://www.rivuspharma.com/
keywords:N/A
$35M
Total Funding
15
Number of Employees
$1.2M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 15 | 15% | $200M |
#2 | $0.6M | 15 | 0% | $4.3M |
#3 | $1.1M | 15 | 7% | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $1.3M | 15 | N/A | N/A |